Roche and UK-based Chugai Pharmaceutical have reported positive data from the Phase III HAVEN 1 clinical trial of emicizumab in patients suffering from haemophilia A.  

Emicizumab is a bispecific monoclonal antibody being developed to combine IXa and X factors that are needed for natural coagulation cascade activation and restoration of blood clotting. 

Created by Chugai, the investigational candidate is being co-developed by the firm with Roche and Genentech.

The HAVEN 1 trial met the primary endpoint with a clinically meaningful and statistically significant decrease of 87% in bleed rate compared to on-demand bypassing agents (BPAs).

The randomised, multi-centre, open-label HAVEN 1 trial evaluated the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous emicizumab prophylaxis in 109 adult and adolescent subjects.

Based on the results, it was found that all the 12 secondary endpoints of the trial were positive with a 79% reduced bleed rate during an intra-patient analysis. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We believe emicizumab has the potential to make a meaningful difference for people with haemophilia A with inhibitors."

Following a median observation time of 31 weeks, results further showed no bleeds with emicizumab in a larger proportion of patients. 

Roche head of global product development and chief medical officer Sandra Horning said: “Based on the bleed reduction shown in the HAVEN 1 and HAVEN 2 studies, we believe emicizumab has the potential to make a meaningful difference for people with haemophilia A with inhibitors, while also reducing the burden of managing the condition with a subcutaneous, once-weekly administration.”

In addition, the firms reported the Phase III HAVEN 2 trial’s interim results were found to be consistent with the results from HAVEN 1. 

HAVEN 2 evaluated the efficacy, safety, and pharmacokinetics of emicizumab in 19 patients under 12 years old.

During the single-arm, multi-centre, open-label trial, an intra-patient comparison revealed a 100% decrease in treated bleeds with once-weekly subcutaneous emicizumab.

Roche has submitted both HAVEN 1 and HAVEN 2 findings to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for approval.